<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93977">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01764555</url>
  </required_header>
  <id_info>
    <org_study_id>APAP study</org_study_id>
    <secondary_id>2012-000956-32</secondary_id>
    <nct_id>NCT01764555</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Acetaminophen in Morbidly Obese Patients</brief_title>
  <acronym>APAP</acronym>
  <official_title>Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Morbidly Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the pharmacokinetics of acetaminophen in morbidly obese patients
      versus normal weight patients. Specifically the different metabolic pathways of
      acetaminophen in morbidly obese adults will be investigated; glucuronidation, sulphation and
      CYP2E1 (cytochrome P450 2E1) oxidation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Clearance (total, glucuronidation, sulphation, CYP2E1 oxidation and unchanged) of acetaminophen in morbidly obese patients in comparison with normal weight patients.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution of acetaminophen in morbidly obese patients in comparison with normal weight patients.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in clearance (total, glucuronidation, sulphation, CYP2E1 oxidation) of acetaminophen in morbidly obese patients at the time of bariatric surgery and at 0.5 - 2 year after bariatric surgery.</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in volume of distribution of acetaminophen in morbidly obese patients at the time of bariatric surgery and at 0.5 - 2 year after bariatric surgery.</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests in morbidly obese patients in comparison with normal weight patients.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>normal weight patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>normal weight patients receiving acetaminophen 2 g instead of 1 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mobidly obese patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>morbidly obese patients receiving acetaminophen 2 g instead of 1 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen 2 g</intervention_name>
    <arm_group_label>normal weight patients</arm_group_label>
    <arm_group_label>mobidly obese patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for morbidly obese patients:

          -  BMI &gt; 40 kg/m2 undergoing bariatric surgery.

          -  Patients between 18 - 60 years old

          -  ASA physical classification of II or III

          -  All racial and ethnic groups will be included

        Inclusion criteria for control group:

          -  BMI between 18 and 25 kg/m2 undergoing general surgery

          -  Patients between 18 - 60 years old

          -  ASA (American Society of Anesthesiology) physical classification of I, II or III

          -  All racial and ethnic groups will be included

        Exclusion criteria for all study arms:

          -  Renal insufficiency

          -  Liver disease

          -  Patients with Gilbert-Meulengracht syndrome

          -  Chronic alcohol intake or use of alcohol within last 72 hours

          -  Pregnancy or breastfeeding

          -  Patients who are treated with drugs know to affect CYP2E1 and UGT (UDP
             glucuronosyltransferase)

          -  Diabetes mellitus type II patients

          -  Smoking

          -  Acetaminophen intake before the study (24 hours before study)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherijne Knibbe, Prof dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne van Rongen, MSc</last_name>
    <phone>030-6093500</phone>
    <email>a.van.rongen@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne van Rongen, MSc</last_name>
      <phone>030-6093500</phone>
      <email>a.van.rongen@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 7, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Catherijne Knibbe</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
